Key facts
- It has raised $2.1M across 4 recorded rounds; the latest was Seed Round ($500K) in Feb 2026.
- Notable investors include Lynda Evans, Wayne Evans.
- Jupiter Biomedical Research has filed 5 Form Ds with the SEC since 2017, most recently Jul 2025 ($221K sold to 8 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Jupiter Biomedical Research
Funding rounds
4 roundsAbout Jupiter Biomedical Research
Developer of disease-curing therapeutics intended to treat brain cancer and other epidermoid tumors. The company develops new drugs and various other products for the treatment of diseases such as brain cancer, measles virus infection, multiple sclerosis and subacute sclerosing panencephalitis, providing patients with better treatments for rare diseases with the help of stem cell technologies.
- Sector
- Healthcare
- HQ
- Palm Beach, FL, United States
- Founded
- 2016
- Ownership
- Privately Held (backing)
Jupiter Biomedical Research doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jupiter Biomedical Research shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jupiter Biomedical Research in its N-PORT filings yet. We sweep new filings monthly.